For Ps & For PsA

1 injection, 4 times a year

after week 0 and week 4 injections¹

For Ps & For PsA

Reliable 3-MONTH DOSING¹

ADMINISTERED BY A SINGLE 150 mg/mL SUBCUTANEOUS INJECTION AT:

Initiation

WEEK 0

WEEK 4

Month 3

WEEK 16

Month 6

WEEK 28

Month 9

WEEK 40

Month 12

WEEK 52

FLEXIBILITY to choose between the 150 mg/mL single-dose pen
or 150 mg/mL single-dose prefilled syringe

The SKYRIZI Pen was awarded an Ease of Use certification from the Arthritis Foundation’s independent lab testing, which included patients with psoriatic arthritis.²

1 INJECTION,
4 TIMES A YEAR¹

after 2 initiation doses
at Week 0 and Week 4

2 administration options¹

for in-office or at-home administration after proper training

1 DOSAGE
FOR ALL PATIENTS¹

regardless of baseline weight,
disease severity, or prior treatment

ADMINISTRATION Considerations

SKYRIZI is intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject SKYRIZI after training in subcutaneous injection technique. Provide proper training to patients and/or caregivers on the subcutaneous injection technique of SKYRIZI according to the Instructions for Use.¹
SKYRIZI may be administered alone or in combination with non-biologic disease-modifying antirheumatic drugs (DMARDs) for patients with active PsA.¹

Download OR EMAIL
DOSING CARD

Download or Email

ADMINISTRATION Considerations

SKYRIZI is intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject SKYRIZI after training in subcutaneous injection technique. Provide proper training to patients and/or caregivers on the subcutaneous injection technique of SKYRIZI according to the Instructions for Use.¹

SKYRIZI may be administered alone or in combination with non-biologic disease-modifying antirheumatic drugs (DMARDs) for patients with active PsA.¹

Download OR EMAIL
DOSING CARD

Download or Email

Considering SKYRIZI
for your patients?

See what coverage for SKYRIZI looks like.

VIEW ACCESS

Man in a blue swimsuit raises his hands in celebration

Already familiar
with SKYRIZI?

Find frequently used forms for your office.

VIEW RESOURCES

INJECTION SUPPORT VIDEOS

150 mg/mL
SKYRIZI PEN

After receiving proper training, your SKYRIZI patients who choose to self-inject can reference this video for additional injection support.

150 mg/mL
PREFILLED SYRINGE

After receiving proper training, your SKYRIZI patients who choose to self-inject can reference this video for additional injection support.

Dosing Schedules

SKYRIZI is the only 4-dose-a-year systemic in psoriasis and psoriatic arthritis that offers a single-dose pen¹

Ps DOSING Ps DOSING

PsA DOSING PsA DOSING

DOSING SCHEDULES FOR SELECT SYSTEMICS FOR MODERATE TO SEVERE Ps^1,3-9*

INJECTION

RECOMMENDED ADULT DOSING

TREATMENT INITIATION

SKYRIZI® (risankizumab-rzaa)

Ps dosing: 150 mg subcutaneous injection; every 12 weeks after initiation

Initiation doses at Weeks 0 and 4

TREMFYA® (guselkumab)

Ps dosing: 100 mg subcutaneous injection; every 8 weeks after initiation

Initiation doses at Weeks 0 and 4

BIMZELX® (bimekizumab-bkzx)

Ps dosing: 320 mg subcutaneous injection (two 160 mg injections);
every 8 weeks after initiation

Initiation doses at Weeks 0, 4, 8, 12, & 16

COSENTYX® (secukinumab)

Ps dosing: one 300 mg injection or two 150 mg injections; every 4 weeks after initiation; for some patients, 150 mg dose may be acceptable

Once-weekly dosing for the first 5 doses

TALTZ® (ixekizumab)

Ps dosing: 80 mg subcutaneous injection; every 4 weeks after initiation

160 mg (two 80 mg injections) at Week 0 followed by 80 mg every 2 weeks through Week 12

ORAL

SOTYKTU™ (deucravacitinib)

Ps dosing: 6 mg oral tablet once daily

None

OTEZLA® (apremilast)

Ps dosing: 30 mg oral tablet twice daily following titration period

Day 1: 10 mg in AM, Day 2: 10 mg in AM and 10 mg in PM, Day 3: 10 mg in AM and 20 mg in PM, Day 4: 20 mg in AM and 20 mg in PM, Day 5: 20 mg in AM and 30 mg in PM

YEARLY DOSING (AFTER INITIATION)

Based on doses required in each 48-week maintenance treatment period

SKYRIZI® (risankizumab-rzaa)

Every 12 Weeks

TREMFYA® (guselkumab)

Every 8 Weeks

BIMZELX® (bimekizumab-bkzx)

Every 8 Weeks

COSENTYX® (secukinumab)

Every 4 Weeks

TALTZ® (ixekizumab)

Every 4 Weeks

SOTYKTU™ (deucravacitinib)

Once Daily

.X 336

OTEZLA® (apremilast)

Twice Daily

. X 672

ILUMYA: Dosing: 100 mg subcutaneous injection; every 12 weeks after
initiation. Initiation doses at Weeks 0 and 4.
1 dot=1 dose

INDICATIONS

SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy and for the treatment of active psoriatic arthritis in adults.

TREMFYA is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy and for the treatment of adult patients with active psoriatic arthritis.

BIMZELX is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

TALTZ is indicated for the treatment of patients 6 years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy and for the treatment of adult patients with active psoriatic arthritis.

COSENTYX is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy and for the treatment of active psoriatic arthritis in patients 2 years of age and older.

SOTYKTU is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

OTEZLA is indicated for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy and for adult patients with active psoriatic arthritis.

ILUMYA is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Products and their designs are trademarks of their respective owners.

This presentation is not intended to compare the efficacy or safety of the treatments shown. While these factors are important, there are additional considerations for selecting a treatment. Please refer to each product’s Prescribing Information for additional information.

SKYRIZI is intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject SKYRIZI after training in subcutaneous injection technique. Instruct patients to read the Instructions for Use before administration.¹

Dosing schedules as of 2/14/2024.

*For select IL-17 inhibitors, select IL-23 inhibitors, a tyrosine kinase 2 inhibitor, and a phosphodiesterase 4 (PDE4) inhibitor.

DOSING SCHEDULES FOR SELECT SYSTEMICS FOR ACTIVE PsA^1,3,5,6,8*

INJECTION

RECOMMENDED ADULT DOSING

TREATMENT INITIATION

SKYRIZI® (risankizumab-rzaa)

PsA dosing: 150 mg subcutaneous injection; every 12 weeks after initiation

Initiation doses at Weeks 0 and 4

TREMFYA® (guselkumab)

PsA dosing: 100 mg subcutaneous injection; every 8 weeks after initiation

Initiation doses at Weeks 0 and 4

COSENTYX® (secukinumab)

PsA dosing: With a loading dosage: 150 mg at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter. Without a loading dosage: 150 mg every 4 weeks. If a patient continues to have active PsA, consider a dosage of 300 mg every 4 weeks.

For patients with PsA and coexistent moderate to severe Ps, the dosing and administration recommendations for Ps should be used.

IV dosing: With a loading dosage: 6 mg/kg at Week 0, followed by 1.75 mg/kg every 4 weeks thereafter (maintenance dosage). Without a loading dosage: 1.75 mg/kg every 4 weeks. Administer as an intravenous infusion over a period of 30 minutes.

Option to dose once-weekly for the first 5 doses or not initiate doses.

TALTZ® (ixekizumab)

PsA recommended dosing: 160 mg by subcutaneous injection (two 80 mg injections) at Week 0, followed by 80 mg every 4 weeks.

For patients with PsA and coexistent moderate to severe Ps, the dosing regimen for adult Ps should be used.

160 mg (two 80 mg injections) at Week 0

ORAL

OTEZLA® (apremilast)

PsA dosing: 30 mg oral tablet twice daily following titration period

Day 1: 10 mg in AM, Day 2: 10 mg in AM and 10 mg in PM, Day 3: 10 mg in AM and 20 mg in PM, Day 4: 20 mg in AM and 20 mg in PM, Day 5: 20 mg in AM and 30 mg in PM

YEARLY DOSING (AFTER INITIATION)

Based on doses required in each 48-week maintenance treatment period

SKYRIZI® (risankizumab-rzaa)

Every 12 Weeks

TREMFYA® (guselkumab)

Every 8 Weeks

COSENTYX® (secukinumab)

Every 4 Weeks

TALTZ® (ixekizumab)

Every 4 Weeks

OTEZLA® (apremilast)

Twice Daily

. X 672

1 dot=1 dose

INDICATIONS

OTEZLA is indicated for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy and for adult patients with active psoriatic arthritis.

Products and their designs are trademarks of their respective owners.

SKYRIZI is intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject SKYRIZI after training in subcutaneous injection technique. Instruct patients to read the Instructions for Use before administration.¹

Dosing schedules as of 2/14/2024.

*For select IL-17 inhibitors, IL-23 inhibitors, and a PDE4 inhibitor.

See Skyrizi Results in Ps

after 1 dose¹⁰

View patient case study

Enroll patients in SKYRIZI complete

Resources for your patients

Enroll Now

Dosing schedules FOR IL-17 and IL-23 INHIBITORS^1-6

asfaf

*Based on doses required in each 48-week maintenance treatment period.

SKYRIZI is intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject SKYRIZI after training in subcutaneous injection technique. Instruct patients to inject 2 prefilled 75 mg syringes for the full 150 mg dose and to read the Instructions for Use before administration.